Tags

Type your tag names separated by a space and hit enter

Androgen Receptor Expression in Endometrial Carcinoma.
Int J Gynecol Pathol. 2018 Mar; 37(2):167-173.IJ

Abstract

Endometrial carcinoma (ECA) is frequently hormonally driven and can be treated with endocrine-based therapy, yet hormone receptor status is not routinely assessed. In particular, little is known about the significance of androgen receptor (AR) in ECA. Androgen has antiproliferative effects in the healthy endometrium and could serve a similar role to progesterone in curbing the progression of estrogen-dependent neoplasia. There may also be a subset of ECA that benefits from androgen antagonistic therapy. We herein investigate AR expression across ECA subtypes and compare its expression to estrogen receptor (ER) and progesterone receptor (PR). Immunohistochemical staining for AR, ER, and PR was performed on an endometrial tissue microarray containing 50 ECA with a variety of morphologic subtypes as well as 20 benign and 9 atypical hyperplastic endometria. AR was expressed by 54% (27/50) of ECA including 60% of low grade endometrioid carcinomas, 70% high grade endometrioid carcinomas, 70% serous carcinomas, 50% carcinosarcomas, and 20% clear cell carcinomas. High AR expression was chiefly restricted to a subset of serous carcinomas (50%). AR expression occurred most often in concert with ER staining, although 5 high grade cancers (1 serous carcinoma, 4 carcinosarcomas) showed AR expression in the absence of ER. In summary, AR positivity is seen in over half of ECA in our study, including the majority of low grade endometrioid carcinomas, high grade endometrioid carcinomas, and serous carcinomas. High level expression is seen in half of serous carcinomas and a subset of serous carcinomas and carcinosarcomas show some degree of AR staining in the absence of ER, suggesting a possible role for androgen inhibition in treatment of these cases.

Authors+Show Affiliations

Departments of Pathology (S.L.Z., A.M.M.) Gynecologic Oncology (L.R.D.), University of Virginia, Charlottesville, Virginia.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28582344

Citation

Zadeh, Sara L., et al. "Androgen Receptor Expression in Endometrial Carcinoma." International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, vol. 37, no. 2, 2018, pp. 167-173.
Zadeh SL, Duska LR, Mills AM. Androgen Receptor Expression in Endometrial Carcinoma. Int J Gynecol Pathol. 2018;37(2):167-173.
Zadeh, S. L., Duska, L. R., & Mills, A. M. (2018). Androgen Receptor Expression in Endometrial Carcinoma. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 37(2), 167-173. https://doi.org/10.1097/PGP.0000000000000401
Zadeh SL, Duska LR, Mills AM. Androgen Receptor Expression in Endometrial Carcinoma. Int J Gynecol Pathol. 2018;37(2):167-173. PubMed PMID: 28582344.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Androgen Receptor Expression in Endometrial Carcinoma. AU - Zadeh,Sara L, AU - Duska,Linda R, AU - Mills,Anne M, PY - 2017/6/6/pubmed PY - 2018/8/21/medline PY - 2017/6/6/entrez SP - 167 EP - 173 JF - International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists JO - Int. J. Gynecol. Pathol. VL - 37 IS - 2 N2 - Endometrial carcinoma (ECA) is frequently hormonally driven and can be treated with endocrine-based therapy, yet hormone receptor status is not routinely assessed. In particular, little is known about the significance of androgen receptor (AR) in ECA. Androgen has antiproliferative effects in the healthy endometrium and could serve a similar role to progesterone in curbing the progression of estrogen-dependent neoplasia. There may also be a subset of ECA that benefits from androgen antagonistic therapy. We herein investigate AR expression across ECA subtypes and compare its expression to estrogen receptor (ER) and progesterone receptor (PR). Immunohistochemical staining for AR, ER, and PR was performed on an endometrial tissue microarray containing 50 ECA with a variety of morphologic subtypes as well as 20 benign and 9 atypical hyperplastic endometria. AR was expressed by 54% (27/50) of ECA including 60% of low grade endometrioid carcinomas, 70% high grade endometrioid carcinomas, 70% serous carcinomas, 50% carcinosarcomas, and 20% clear cell carcinomas. High AR expression was chiefly restricted to a subset of serous carcinomas (50%). AR expression occurred most often in concert with ER staining, although 5 high grade cancers (1 serous carcinoma, 4 carcinosarcomas) showed AR expression in the absence of ER. In summary, AR positivity is seen in over half of ECA in our study, including the majority of low grade endometrioid carcinomas, high grade endometrioid carcinomas, and serous carcinomas. High level expression is seen in half of serous carcinomas and a subset of serous carcinomas and carcinosarcomas show some degree of AR staining in the absence of ER, suggesting a possible role for androgen inhibition in treatment of these cases. SN - 1538-7151 UR - https://www.unboundmedicine.com/medline/citation/28582344/Androgen_Receptor_Expression_in_Endometrial_Carcinoma_ L2 - http://dx.doi.org/10.1097/PGP.0000000000000401 DB - PRIME DP - Unbound Medicine ER -